HER-2 Gene Amplification clinical trials at UCLA
1 research study open to eligible people
open to eligible people ages 18 years and up
This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors. The study consists of two parts: a Part 1 Dose Escalation and Part 2 Dose Expansion.
Los Angeles, California and other locations
Our lead scientists for HER-2 Gene Amplification research studies include Nicolaos J Palaskas, MD, PhD.